Alzheimer's Drug Reduces Chagas Disease Infection in Mice

The drug, called memantine, could enter clinical trials to determine its effectiveness in humans.
Source: The Scientist - Category: Science Tags: The Literature Source Type: news

Related Links:

Publication date: Available online 20 January 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAuthor(s): Oscar Campetella, Carlos A. Buscaglia, Juan Mucci, María Susana LeguizamónAbstractMany important pathogen-host interactions rely on highly specific carbohydrate binding events. In the case of the protozoan Trypanosoma cruzi, the causative agent of Chagas disease, glycointeractions involving sialic acid (SA) residues are pivotal for parasite infectivity, escape from immune surveillance and pathogenesis. Though unable to synthesize SA de novo, T. cruzi displays a unique trans-Sial...
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research
TUESDAY, Jan. 21, 2020 -- No harms come from screening for Alzheimer disease and related dementias (ADRDs) in primary care, according to a study recently published in the Journal of the American Geriatrics Society. Nicole R. Fowler, Ph.D., from the...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
Authors: Baranowska-Wójcik E, Szwajgier D Abstract Introduction: Alzheimer's Disease (AD) is a progressive neurodegenerative pathology characterised by the presence of neuritic plaques and neurofibrillary tangles. The most important markers in AD pathology include excessive accumulation of amyloid beta (Aβ42) and phosphorylated tau (P-tau) proteins. One of the possible therapeutic strategies entails the elimination of such deposits by inhibiting Aβ aggregation. For years, one of the major problems in the treatment of AD has been the limited ability to deliver drugs to the brain for reasons related to ...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
ConclusionsOur data showed that Alzheimer's Disease is not characterised by accelerated long term forgetting, patients in our sample forgot at the same rate as healthy controls. Given the additional trials required by Alzheimer's patients to reach the 70% correct criterion, their memory impairment appears to be one of encoding. Moreover, Alzheimer's Disease patients benefited from repeated testing to the same extent as healthy controls. Due to our methodological design, we were also able to show that performance improved under repeated testing conditions, even with partial testing (sampling different features from each nar...
Source: Neuropsychologia - Category: Neurology Source Type: research
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
AbstractPurposeAlthough most deep learning (DL) studies have reported excellent classification accuracy, these studies usually target typical Alzheimer ’s disease (AD) and normal cognition (NC) for which conventional visual assessment performs well. A clinically relevant issue is the selection of high-risk subjects who need active surveillance among equivocal cases. We validated the clinical feasibility of DL compared with visual rating or quanti tative measurement for assessing the diagnosis and prognosis of subjects with equivocal amyloid scans.Methods18F-florbetaben scans of 430 cases (85 NC, 233 mild cognitive im...
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
ConclusionMedial and lateral temporal regions represent a site of significant tau accumulation in A+ subjects and possibly a useful marker of early clinical changes. This is the first study in which the A/T/N model is applied using 18F-flortaucipir PET in a memory clinic population. The majority of patients showed a profile consistent with the Alzheimer ’s continuum, while a minor percentage showed a profile suggestive of possible other neurodegenerative diseases. These results support the applicability of the A/T/N model in clinical practice.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Publication date: Available online 20 January 2020Source: NeurocomputingAuthor(s): Wei Li, Xuefeng Lin, Xi ChenAbstractApplying machine learning methods to various modality medical images and clinical data for early diagnosis of Alzheimer's disease (AD) and its prodromal stage has got lots of significant results. So far, the image data input to classifier mainly focus on 2D or 3D images. Although some functional imaging technologies, such as functional magnetic resonance imaging (fMRI), generate 4D data which contain both spatial and time-varying information of the brain, for the lack of suitable 4D image processing algori...
Source: Neurocomputing - Category: Neuroscience Source Type: research
(Case Western Reserve University) Researchers at the Case Western University School of Medicine in Cleveland, Ohio say they have identified a previously unknown gene and associated protein (which they have named 'aggregatin') which could potentially be suppressed to slow the advance of Alzheimer's disease. 'Based on the data we have, this protein can be an unrecognized new risk factor for Alzheimer's disease (AD),' said Xinglong Wang, an associate professor of pathology at the School of Medicine.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Abstract Cysteine proteases are essential hydrolytic enzymes present in the majority of organisms, including viruses and unicellular parasites. Despite the high sequence identity displayed among these proteins, specific structural features across different species grant distinct functions to these biomolecules, frequently related to pathological conditions. Consequently, their relevance as promising targets for potential specific inhibitors has been highlighted and occasionally validated in recent decades. In this review, we discuss the recent outcomes on structure-based campaigns aiming the discovery of new inhib...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
More News: Alzheimer's | Chagas Disease | Clinical Trials | Namenda | Science